Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation

Dong Oh Kang, Cheol Woong Yu, Hee Dong Kim, Jae Young Cho, Hyung Joon Joo, Rak Kyong Choi, Jin Sik Park, Hyun Jong Lee, Je Sang Kim, Jae Hyung Park, Soon Jun Hong, Do-Sun Lim

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background The optimal antithrombotic regimen in patients with atrial fibrillation (AF) undergoing drug-eluting stent (DES) implantation for complex coronary artery disease is unclear. We compared the net clinical outcomes of triple antithrombotic therapy (TAT; aspirin, thienopyridine, and warfarin) and dual antiplatelet therapy (DAPT; aspirin and thienopyridine) in AF patients who had undergone DES implantation. Methods A total of 367 patients were enrolled and analyzed retrospectively; 131 patients (35.7%) received TAT and 236 patients (64.3%) received DAPT. DAPT and warfarin were maintained for a minimum of 12 and 24 months, respectively. The primary endpoint was the 2-year net clinical outcomes, a composite of major bleeding and major adverse cardiac and cerebral events (MACCE). Propensity score-matching analysis was carried out in 99 patient pairs. Results The 2-year net clinical outcomes of the TAT group were worse than those of the DAPT group (34.3 vs. 21.1%, P=0.006), which was mainly due to the higher incidence of major bleeding (16.7 vs. 4.6%, P<0.001), without any significant increase in MACCE (22.1 vs. 17.7%, P=0.313). In the multivariate analysis, TAT was an independent predictor of worse net clinical outcomes (odds ratio 1.63, 95% confidence interval 1.06-2.50) and major bleeding (odds ratio 3.54, 95% confidence interval 1.65-7.58). After propensity score matching, the TAT group still had worse net clinical outcomes and a higher incidence of major bleeding compared with the DAPT group. Conclusion In AF patients undergoing DES implantation, prolonged administration of TAT may be harmful due to the substantial increase in the risk for major bleeding without any reduction in MACCE.

Original languageEnglish
Pages (from-to)372-380
Number of pages9
JournalCoronary Artery Disease
Volume26
Issue number5
DOIs
Publication statusPublished - 2015 Jul 11

Fingerprint

Drug-Eluting Stents
Atrial Fibrillation
Hemorrhage
Propensity Score
Warfarin
Therapeutics
Aspirin
Odds Ratio
Confidence Intervals
Incidence
Coronary Artery Disease
Multivariate Analysis

Keywords

  • atrial fibrillation
  • drug-eluting stent
  • dual antiplatelet therapy
  • triple antithrombotic therapy
  • warfarin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation. / Kang, Dong Oh; Yu, Cheol Woong; Kim, Hee Dong; Cho, Jae Young; Joo, Hyung Joon; Choi, Rak Kyong; Park, Jin Sik; Lee, Hyun Jong; Kim, Je Sang; Park, Jae Hyung; Hong, Soon Jun; Lim, Do-Sun.

In: Coronary Artery Disease, Vol. 26, No. 5, 11.07.2015, p. 372-380.

Research output: Contribution to journalArticle

Kang, Dong Oh ; Yu, Cheol Woong ; Kim, Hee Dong ; Cho, Jae Young ; Joo, Hyung Joon ; Choi, Rak Kyong ; Park, Jin Sik ; Lee, Hyun Jong ; Kim, Je Sang ; Park, Jae Hyung ; Hong, Soon Jun ; Lim, Do-Sun. / Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation. In: Coronary Artery Disease. 2015 ; Vol. 26, No. 5. pp. 372-380.
@article{b0959196c0184d24be4c5d7d0997949e,
title = "Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation",
abstract = "Background The optimal antithrombotic regimen in patients with atrial fibrillation (AF) undergoing drug-eluting stent (DES) implantation for complex coronary artery disease is unclear. We compared the net clinical outcomes of triple antithrombotic therapy (TAT; aspirin, thienopyridine, and warfarin) and dual antiplatelet therapy (DAPT; aspirin and thienopyridine) in AF patients who had undergone DES implantation. Methods A total of 367 patients were enrolled and analyzed retrospectively; 131 patients (35.7{\%}) received TAT and 236 patients (64.3{\%}) received DAPT. DAPT and warfarin were maintained for a minimum of 12 and 24 months, respectively. The primary endpoint was the 2-year net clinical outcomes, a composite of major bleeding and major adverse cardiac and cerebral events (MACCE). Propensity score-matching analysis was carried out in 99 patient pairs. Results The 2-year net clinical outcomes of the TAT group were worse than those of the DAPT group (34.3 vs. 21.1{\%}, P=0.006), which was mainly due to the higher incidence of major bleeding (16.7 vs. 4.6{\%}, P<0.001), without any significant increase in MACCE (22.1 vs. 17.7{\%}, P=0.313). In the multivariate analysis, TAT was an independent predictor of worse net clinical outcomes (odds ratio 1.63, 95{\%} confidence interval 1.06-2.50) and major bleeding (odds ratio 3.54, 95{\%} confidence interval 1.65-7.58). After propensity score matching, the TAT group still had worse net clinical outcomes and a higher incidence of major bleeding compared with the DAPT group. Conclusion In AF patients undergoing DES implantation, prolonged administration of TAT may be harmful due to the substantial increase in the risk for major bleeding without any reduction in MACCE.",
keywords = "atrial fibrillation, drug-eluting stent, dual antiplatelet therapy, triple antithrombotic therapy, warfarin",
author = "Kang, {Dong Oh} and Yu, {Cheol Woong} and Kim, {Hee Dong} and Cho, {Jae Young} and Joo, {Hyung Joon} and Choi, {Rak Kyong} and Park, {Jin Sik} and Lee, {Hyun Jong} and Kim, {Je Sang} and Park, {Jae Hyung} and Hong, {Soon Jun} and Do-Sun Lim",
year = "2015",
month = "7",
day = "11",
doi = "10.1097/MCA.0000000000000242",
language = "English",
volume = "26",
pages = "372--380",
journal = "Coronary Artery Disease",
issn = "0954-6928",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation

AU - Kang, Dong Oh

AU - Yu, Cheol Woong

AU - Kim, Hee Dong

AU - Cho, Jae Young

AU - Joo, Hyung Joon

AU - Choi, Rak Kyong

AU - Park, Jin Sik

AU - Lee, Hyun Jong

AU - Kim, Je Sang

AU - Park, Jae Hyung

AU - Hong, Soon Jun

AU - Lim, Do-Sun

PY - 2015/7/11

Y1 - 2015/7/11

N2 - Background The optimal antithrombotic regimen in patients with atrial fibrillation (AF) undergoing drug-eluting stent (DES) implantation for complex coronary artery disease is unclear. We compared the net clinical outcomes of triple antithrombotic therapy (TAT; aspirin, thienopyridine, and warfarin) and dual antiplatelet therapy (DAPT; aspirin and thienopyridine) in AF patients who had undergone DES implantation. Methods A total of 367 patients were enrolled and analyzed retrospectively; 131 patients (35.7%) received TAT and 236 patients (64.3%) received DAPT. DAPT and warfarin were maintained for a minimum of 12 and 24 months, respectively. The primary endpoint was the 2-year net clinical outcomes, a composite of major bleeding and major adverse cardiac and cerebral events (MACCE). Propensity score-matching analysis was carried out in 99 patient pairs. Results The 2-year net clinical outcomes of the TAT group were worse than those of the DAPT group (34.3 vs. 21.1%, P=0.006), which was mainly due to the higher incidence of major bleeding (16.7 vs. 4.6%, P<0.001), without any significant increase in MACCE (22.1 vs. 17.7%, P=0.313). In the multivariate analysis, TAT was an independent predictor of worse net clinical outcomes (odds ratio 1.63, 95% confidence interval 1.06-2.50) and major bleeding (odds ratio 3.54, 95% confidence interval 1.65-7.58). After propensity score matching, the TAT group still had worse net clinical outcomes and a higher incidence of major bleeding compared with the DAPT group. Conclusion In AF patients undergoing DES implantation, prolonged administration of TAT may be harmful due to the substantial increase in the risk for major bleeding without any reduction in MACCE.

AB - Background The optimal antithrombotic regimen in patients with atrial fibrillation (AF) undergoing drug-eluting stent (DES) implantation for complex coronary artery disease is unclear. We compared the net clinical outcomes of triple antithrombotic therapy (TAT; aspirin, thienopyridine, and warfarin) and dual antiplatelet therapy (DAPT; aspirin and thienopyridine) in AF patients who had undergone DES implantation. Methods A total of 367 patients were enrolled and analyzed retrospectively; 131 patients (35.7%) received TAT and 236 patients (64.3%) received DAPT. DAPT and warfarin were maintained for a minimum of 12 and 24 months, respectively. The primary endpoint was the 2-year net clinical outcomes, a composite of major bleeding and major adverse cardiac and cerebral events (MACCE). Propensity score-matching analysis was carried out in 99 patient pairs. Results The 2-year net clinical outcomes of the TAT group were worse than those of the DAPT group (34.3 vs. 21.1%, P=0.006), which was mainly due to the higher incidence of major bleeding (16.7 vs. 4.6%, P<0.001), without any significant increase in MACCE (22.1 vs. 17.7%, P=0.313). In the multivariate analysis, TAT was an independent predictor of worse net clinical outcomes (odds ratio 1.63, 95% confidence interval 1.06-2.50) and major bleeding (odds ratio 3.54, 95% confidence interval 1.65-7.58). After propensity score matching, the TAT group still had worse net clinical outcomes and a higher incidence of major bleeding compared with the DAPT group. Conclusion In AF patients undergoing DES implantation, prolonged administration of TAT may be harmful due to the substantial increase in the risk for major bleeding without any reduction in MACCE.

KW - atrial fibrillation

KW - drug-eluting stent

KW - dual antiplatelet therapy

KW - triple antithrombotic therapy

KW - warfarin

UR - http://www.scopus.com/inward/record.url?scp=84936950340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936950340&partnerID=8YFLogxK

U2 - 10.1097/MCA.0000000000000242

DO - 10.1097/MCA.0000000000000242

M3 - Article

VL - 26

SP - 372

EP - 380

JO - Coronary Artery Disease

JF - Coronary Artery Disease

SN - 0954-6928

IS - 5

ER -